Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nasdaq Biotechnology Ishares ETF (NQ: IBB )

131.92 -1.04 (-0.78%)
Streaming Delayed Price Updated: 11:18 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nasdaq Biotechnology Ishares ETF

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
22 23 Next >
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
4 Healthcare Funds With "Double Discounts"
There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look... 
Via Talk Markets
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
How To Prepare For Monday By Watching Trading Range Lows
After both the Russell 2000 and the Nasdaq 100 failed to hold or clear over the 50-Day moving average, the bleeding has not stopped. Now that IWM and many key ETFs are near the bottom of their trading... 
Via Talk Markets
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Pfizer: What Comes After the Covid-19 Fire?
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles. 
Via InvestorPlace
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Does the Nasdaq 100 Index Have a Chokehold on the Stock Market?
Wednesday, the stock market stuck with its choppy trend. 
Via Talk Markets
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Real Motion Shows Hidden Momentum in the Russell 2000 and S&P 500
While the market is choppy and traders should be extra careful, if Wednesday shows follow-through in both price and momentum, we can watch for Tuesday’s rally to continue. 
Via Talk Markets
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
Will the Market Pick a Direction On Monday?
When the indices are tough to read, it can help to watch other symbols like JNK and VXX. 
Via Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
Why We Bought Invesco Agricultural Fund (DBA)
One problem with soft commodities is when countries need more food, there is no instant fix, as it takes time to grow. Along with drought and other potential issues, it could take another 2 to 3 years... 
Via Talk Markets
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Keep Eyes on Momentum in the Small-Cap Index and The Biotech Space
If BIIB can clear and close over roughly $212, it would confirm that price and momentum agree and show it's potentially ready for another move higher. 
Via Talk Markets
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Regional Banking (KRE) Holds onto Support and Momentum
If the regional banking space can make a quick turnaround Silvergate Capital could be one company that leads the way higher. 
Via Talk Markets
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
22 23 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.